Long-Term Evaluation of Safety and Health-Related Quality of Life in Women with Heavy Menstrual Bleeding Treated with Oral Tranexamic Acid

Muse, Ken N.; Lukes, Andrea S.; Gersten, Janet; Waldbaum, Arthur; Mabey, R. Garn; Trott, Edward A.

doi:10.2217/whe.11.65

Cited by 21 publications

(15 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study indicated that HRQL improved in women with menorrhagia and abnormal laboratory hemo stasis when they were treated with either tranexamic acid or intranasal desmopressin; tranexamic acid proved to be more effective [16]. Recent studies have shown that TA, in addition to reducing mean MBL per cycle, also has a positive impact on HRQL [12][13][14] as measured by the validated Menorrhagia Impact Questionnaire (MIQ) [17].…”

mentioning

confidence: 99%

Daily Menstrual Blood Loss and Quality of Life in Women with Heavy Menstrual Bleeding

Lukes

Baker²,

Eder³

et al. 2012

Womens Health (Lond Engl)

Self Cite

View full text Add to dashboard Cite

Highest daily MBLs occurred on days 2 and 3 of menstrual cycles. Women's perceptions of daily MBL were consistent with objective measures of MBL. Higher daily MBL was related to increased limitations in physical activities and limitations in social/leisure activities. Daily MBL values were consistent with women's perceptions of MBL. Reduced daily MBL was associated with improvements in health-related quality of life.

show abstract

mentioning

confidence: 99%

Daily Menstrual Blood Loss and Quality of Life in Women with Heavy Menstrual Bleeding

Lukes

Baker²,

Eder³

et al. 2012

Womens Health (Lond Engl)

Self Cite

View full text Add to dashboard Cite

show abstract

“…It improves symptoms of HMB generally within three cycles, reducing menstrual blood flow by 29–58% (Lethaby et al , ; Lukes et al , ). If effective, it can be used long term (Muse et al , ). Tranexamic acid improves HRQL, haemoglobin and ferritin levels in women with HMB (Winkler, ; Lukes et al , , ; Muse et al , , ).…”

Section: Managementmentioning

confidence: 99%

“…If effective, it can be used long term (Muse et al , ). Tranexamic acid improves HRQL, haemoglobin and ferritin levels in women with HMB (Winkler, ; Lukes et al , , ; Muse et al , , ). The risk of thrombosis is controversial.…”

Section: Managementmentioning

confidence: 99%

How I manage heavy menstrual bleeding

2013

View full text Add to dashboard Cite

SummaryHeavy menstrual bleeding (HMB) is a common clinical problem; population-based studies estimate that approximately 10-35% of women report this symptom during their lifetime, while about 5% of women consult a physician for evaluation of HMB. Patients with HMB account for 15% of all referrals to gynaecologists and are frequently seen by haematologists in bleeding disorder clinics as well. Heavy menstrual bleeding can be caused by a wide variety of local and systemic factors, so a careful clinical and laboratory evaluation is often necessary to determine the aetiology and guide appropriate management. This review discusses the definition, causes and clinical outcomes of HMB. It outlines a diagnostic approach and focuses on medical (as opposed to surgical) treatments. Throughout, areas of controversy and opportunities for further research are highlighted.

show abstract

“…TA is a Food and Drug Administration-approved hemostatic agent for the treatment of traumatic bleeding and is also available over-the-counter elsewhere for indications such as heavy menstrual bleeding (Dunn and Goa, 1999;McCormack, 2012). As a hemostatic agent, TA is reported to have a favorable safety profile for existing indications Muse et al, 2011) and has been demonstrated as an inexpensive and effective treatment for traumatic bleeding, as suggested recently by the multicenter Clinical Randomization of an Antifibrinolytic in Significant Hemorrhage-2 trial (Roberts et al, 2011). In agreement with our findings in plasminogen-null mice, administration of TA also attenuated acetaminophen hepatotoxicity in mice, albeit to a lesser extent (Sullivan et al, 2012b).…”

Section: Introductionmentioning

confidence: 99%

The Antifibrinolytic Drug Tranexamic Acid Reduces Liver Injury and Fibrosis in a Mouse Model of Chronic Bile Duct Injury

Joshi

Kopec

Towery

et al. 2014

The Journal of Pharmacology and Experimental Therapeutics

View full text Add to dashboard Cite

Hepatic fibrin deposition has been shown to inhibit hepatocellular injury in mice exposed to the bile duct toxicant a-naphthylisothiocyanate (ANIT). Degradation of fibrin clots by fibrinolysis controls the duration and extent of tissue fibrin deposition. Thus, we sought to determine the effect of treatment with the antifibrinolytic drug tranexamic acid (TA) and plasminogen activator inhibitor-1 (PAI-1) deficiency on ANIT-induced liver injury and fibrosis in mice. Plasmin-dependent lysis of fibrin clots was impaired in plasma from mice treated with TA (1200 mg/kg i.p., administered twice daily). Prophylactic TA administration reduced hepatic inflammation and hepatocellular necrosis in mice fed a diet containing 0.025% ANIT for 2 weeks. Hepatic type 1 collagen mRNA expression and deposition increased markedly in livers of mice fed ANIT diet for 4 weeks. To determine whether TA treatment could inhibit this progression of liver fibrosis, mice were fed ANIT diet for 4 weeks and treated with TA for the last 2 weeks. Interestingly, TA treatment largely prevented increased deposition of type 1 collagen in livers of mice fed ANIT diet for 4 weeks. In contrast, biliary hyperplasia/inflammation and liver fibrosis were significantly increased in PAI-1 2/2 mice fed ANIT diet for 4 weeks. Overall, the results indicate that fibrinolytic activity contributes to ANIT diet-induced liver injury and fibrosis in mice. In addition, these proof-of-principle studies suggest the possibility that therapeutic intervention with an antifibrinolytic drug could form a novel strategy to prevent or reduce liver injury and fibrosis in patients with liver disease.

show abstract

Long-Term Evaluation of Safety and Health-Related Quality of Life in Women with Heavy Menstrual Bleeding Treated with Oral Tranexamic Acid

Abstract: Long-term TA treatment was well tolerated and improved measures of HRQoL in women with cyclic HMB.

Cited by 21 publications

References 19 publications

Daily Menstrual Blood Loss and Quality of Life in Women with Heavy Menstrual Bleeding

Daily Menstrual Blood Loss and Quality of Life in Women with Heavy Menstrual Bleeding

How I manage heavy menstrual bleeding

The Antifibrinolytic Drug Tranexamic Acid Reduces Liver Injury and Fibrosis in a Mouse Model of Chronic Bile Duct Injury

Contact Info

Product

Resources

About